Stec G P, Atkinson A J, Nevin M J, Thenot J P, Ruo T I, Gibson T P, Ivanovich P, del Greco F
Clin Pharmacol Ther. 1979 Nov;26(5):618-28. doi: 10.1002/cpt1979265618.
NAPA pharmacokinetics were studied in 6 functionally anephric patients. Distribution and nonrenal elimination of this drug were found to be the same as in individuals with normal renal function but renal clearance was reduced, resulting in a mean elimination t 1/2 of 41.9 hr (6.2 hr in normal subjects). Renal clearance of NAPA correlated well with ClCr. Dialysis removed NAPA from both red blood cells and plasma and increased ClT approximately fourfold. Dialysis itself resulted in a 77% reduction in ClS that limited the total amount of NAPA removed by this procedure. This reduction in ClS was sustained for at least 3 hr after dialysis and attenuated rebound in plasma NAPA concentrations.
对6名功能性无肾患者的NAPA药代动力学进行了研究。发现该药物的分布和非肾清除与肾功能正常的个体相同，但肾清除率降低，导致平均消除半衰期为41.9小时（正常受试者为6.2小时）。NAPA的肾清除率与肌酐清除率密切相关。透析可从红细胞和血浆中清除NAPA，并使总清除率增加约四倍。透析本身导致系统清除率降低77%，这限制了通过该程序清除的NAPA总量。透析后，这种系统清除率的降低持续至少3小时，并减弱了血浆中NAPA浓度的反跳。
